First-Line Cemiplimab + Chemotherapy Improves Quality of Life and Delays Disease Deterioration in Advanced NSCLC Without Driver Mutations
The results of the EMPOWER-Lung 3 study support the use of cemiplimab in combination with chemotherapy as a first-line treatment option for patients with advanced NSCLC without driver mutations.
Få tilgang
Hvis du er lege, sykepleier eller annen helsepersonell, kan du få tilgang til hele artikkelen ved å opprette en profil på BestPractice Nordic.
- Få tilgang
- Hvis du allerede har en profil: Logg in
